Miles Laboratories, Inc.

Mobay Corporation

Other

Bayer Corporation

Miles Inc.

Sharon A Bryant

Karen K Brown

Richard E Parizek

Nathan D Greene

Sandy L Trump

George P Shibley

Richard C Stewart

Ivo Van De Rijn

Louis J Travalent

Linda L Ruiz

Michael J McGinley

Kenneth S Lewis

Lonny E Vlieger

Leszek J Choromanski

Stuart K Nibbelink

Larry F Moore

Curtis D Wilson

Disclosed herein is a multicomponent low dose vaccine comprising a safe and immunogenically effective combination of a protective antigen component or components of clostridial organism, a protective antigen component of a non-clostridial organism and an adjuvant.

Multicomponent vaccine containing clostridial and non-clostridial organisms in a low dose

Disclosed herein is a device for storing and/or delivering an effective amount of biological or pharmaceutical material to an animal comprising a tube disposed to contain said biological or pharmaceutical material and sealed at its ends and adapted to provide an opening through which the biological or pharmaceutical material exits and is administered to an intended site of the animal.

Device for storage and mucosal delivery of biological or pharmaceutical materials to animals

A vaccine effective against S. zooepidemicus-caused infections is made by enzymatic digestion of S. zooepidemicus and subsequent detergent treatment of the product of this digestion. The antigenic material thus obtained is then combined with an appropriate adjuvant.

Preparation and use of enzyme-detergent extracted Streptococcus

The present disclosure is concerned with the production of high molecular weight hyaluronic acid suitable for medicinal administration to mammals without provoking an immune response from microbiological fermentation. The cultures may be prepared from specially developed strains of hyaluronic acid generating bacteria obtained by passaging in serologically negative host animal blood. The cultures are kept in log phase growth for an extended period by appropriate temperature, pH and glucose content adjustments. If the cultured strain is not hyaluronidase negative the hyaluronidase activity is inhibited. The hyaluronic acid is precipitated from the culture by the sequential addition of an anionic surfactant and then a cationic surfactant and extended from the precipitate with a high molarity aqueous calcium ion solution. The isolated aqueous hyaluronic acid solution may then be purified by passage through a nitrocellulose filter. Its pyrogenicity may be alleviated by treatment with a strong acid washed activated carbon.

Method for the microbiological production of non-antigenic hyaluronic

The present disclosure is concerned with procedures for adjusting the average molecular weight, the molecular weight distribution and the viscosity in solution of hyaluronic acid and its salts (HA), particularly its sodium and potassium salts. The average molecular weight can be increased and the molecular weight distribution can be narrowed by precipitating this material into a bath of a non-solvent containing a continuously moving device to which it can adhere as it precipitates. The solution viscosity of this or any high molecular weight, high viscosity HA can be reduced without substantially effecting its molecular weight by either a moderate temperature heat treatment or passage through a fine (one micron or less) pore filter as a one weight percent or stronger aqueous solution. The disclosure is also concerned with the high molecular weight low solution viscosity HA so obtained.

Low viscosity high molecular weight filter sterilizable hyaluronic acid

A device for administering antigenic material to a horse intranasally. This device is composed of a hollow tube and a blocking device. The hollow tube is long enough to reach the tonsilor tissue of a horse. This tube has a sealed end and a tapered open end. At least one opening, preferably openings along the length of this tube are positioned in a manner such that antigenic material which exits through them will reach the tonsilor tissue of the horse. The blocking device sits on the hollow tube at the point where the tapering of the open end begins. A syringe containing antigenic material is positioned at the tapered open end of the hollow tube and the antigenic material is then released in the form of small droplets on the tonsilor tissue of the horse.

Applicator for intranasal administration of vaccines to horses

Horses can be immunized by the intranasal administration of antigenic material which provokes the proliferation of antibodies which reduce or neutralize the virulence of invasive microorganisms. These antigenic materials may be inactivated whole organisms, extracts from such organisms, or recombinant DNA or synthetic peptide antigens. This antigenic material can be combined with adjuvants and transdermal carriers or it can just be carried in sterile water. The intranasal vaccination may be part of a total regimen that includes other routes of administration such as intramuscular injection.

Intranasal vaccination of horses with inactivated microorganisms or

Immunogenic protein material obtained from Streptococcus equi bacteria via enzymatic digestion and detergent treatment and useful as a vaccine.

Preparation and use of enzyme-detergent extracted Streptococcus equi

Antigenicity of streptococcal preparations useful for inducing anti-streptococcal immunity in animals can be determined using a combining power technique. Method involves incubating serial dilutions of the antigen preparation with known amounts of anti-streptococcal antiserum, thereby lessening, in serial manner, the combining power of the antiserum. The serial reaction products are then incubated with serial dilutions of streptococcal preparations having known activity and the effects of the serial reaction products on such activity are then determined by in vivo means. Those determinations can be related to a standard for determining potency of the streptococcal preparation. Assay technique is especially useful in determining potency of Streptococcus equi bacterins or bacterin derivatives.

Determining potency of streptococcal preparations

Group C streptococcal antibody levels in a serum sample can be determined via passive protection test in susceptible animals. Test is based on property of protective antibody in the serum sample to reduce the virulence of a group C streptococcal challenge and provides a means for detecting whether an animal (e.g. horse) is susceptible to infection by group C streptococcal organism.

Growing community of inventors

Shawnee, KS, United States of America

Sharon A Bryant